Sorrento Therapeutics (SRNE) Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), a license and development partner, will present posters at this year’s American Society of Clinical Oncology (ASCO) meeting to be held June 5-6, 2021, releasing Phase 1 data for its HER2-ADC, A166. To generate this site-specific third generation antibody drug conjugate (ADC), Kelun partnered with Levena Biopharma, a wholly owned subsidiary of Sorrento, which provided the patent-protected technologies for the generation and production of A166, including (1) a proprietary small molecule toxin, Duostatin-5, a tubulin inhibitor, (2) K-Lock, a site-specific conjugation technology and (3) an enzymatically cleavable linker. Compared to its commercial competitors, A166 demonstrated a better safety profile in the initial study and potentially better efficacy, as shown in the overall response rate (ORR) of 71.4% (A166) at 6.0 mg/kg vs DS-8201, which has an ORR of 60.9% (DS-8201) at 5.4 mg/kg.

Clinical Trial Information:

Clinical Trial Registry Number:CTR20181301Citation:J Clin Oncol 39, 2021 (suppl 15; abstr 1024)DOI:10.1200/JCO.2021.39.15_suppl.1024

You May Also Be Interested In

• Hepion Pharmaceuticals (HEPA) Winds Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
• Cybin Inc (CYBN) Reports Publication of Research Manuscript in the Journal of Medicinal Chemistry
• Imunon's (IMNN) IND Application Cleared to Begin Human Testing of IMNN-101